scispace - formally typeset
Search or ask a question
Institution

Israel Ministry of Health

GovernmentJerusalem, Israel
About: Israel Ministry of Health is a government organization based out in Jerusalem, Israel. It is known for research contribution in the topics: Population & Public health. The organization has 1633 authors who have published 2108 publications receiving 65387 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: This study suggests a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine in mothers using selective serotonin reuptake inhibitors.
Abstract: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In recent years there has been concern regarding the possibility that selective serotonin reuptake inhibitors (SSRIs) cause an increased rate of congenital cardiovascular anomalies. • As of today, there is still debate in the literature as to the possible effects of paroxetine and fluoxetine on the embryonic cardiovascular system. WHAT THIS STUDY ADDS • Based on prospective data from three Teratogen Information Services, we have demonstrated an increased rate of congenital cardiovascular anomalies among the offspring of fluoxetine- and paroxetine-treated mothers. AIMS Recent studies have suggested a possible association between maternal use of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy and cardiovascular anomalies. The aim of the present study was to evaluate the teratogenic risk of paroxetine and fluoxetine. METHODS This multicentre, prospective, controlled study evaluated the rate of major congenital anomalies after first-trimester gestational exposure to paroxetine, fluoxetine or nonteratogens. RESULTS We followed up 410 paroxetine, 314 fluoxetine first-trimester exposed pregnancies and 1467 controls. After exclusion of genetic and cytogenetic anomalies, there was a higher rate of major anomalies in the SSRI groups compared with the controls [paroxetine 18/348 (5.2%), fluoxetine 12/253 (4.7%) and controls 34/1359 (2.5%)]. The main risk applied to cardiovascular anomalies [paroxetine 7/348 (2.0%), crude odds ratio (OR) 3.47, 95% confidence interval (CI) 1.13, 10.58; fluoxetine 7/253 (2.8%), crude OR, 4.81 95% CI 1.56, 14.71; and controls 8/1359 (0.6%)]. On logistic regression analysis only cigarette smoking of ≥10 cigarettes day−1 and fluoxetine exposure were significant variables for cardiovascular anomalies. The adjusted ORs for paroxetine and fluoxetine were 2.66 (95% CI 0.80, 8.90) and 4.47 (95% CI 1.31, 15.27), respectively. CONCLUSION This study suggests a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine.

189 citations

Journal ArticleDOI
TL;DR: From August 1 to October 31, 2000, 417 cases of West Nile fever were serologically confirmed throughout Israel; 326 (78%) were hospitalized patients; there were 35 deaths, and age-specific case-fatality rate increased with age.
Abstract: From August 1 to October 31, 2000, 417 cases of West Nile (WN) fever were serologically confirmed throughout Israel; 326 (78%) were hospitalized patients. Cases were distributed throughout the country; the highest incidence was in central Israel, the most populated part. Men and women were equally affected, and their mean age was 54+/-23.8 years (range 6 months to 95 years). Incidence per 1,000 population increased from 0.01 in the 1st decade of life to 0.87 in the 9th decade. There were 35 deaths (case-fatality rate 8.4%), all in patients >50 years of age. Age-specific case-fatality rate increased with age. Central nervous system involvement occurred in 170 (73%) of 233 hospitalized patients. The countrywide spread, number of hospitalizations, severity of the disease, and high death rate contrast with previously reported outbreaks in Israel.

188 citations

Journal ArticleDOI
TL;DR: No increase in genetic defects or congenital malformations was detected among children conceived to parents who have previously undergone chemotherapy or radiotherapy, and the use of assisted reproductive technologies and micromanipulation techniques might increase this risk.
Abstract: Male and female germ cells vary in their sensitivity to the mutagenic effects of chemotherapy and radiotherapy, depending on their stage of maturation and the agent used Although sperm DNA damage exists following treatment, no increase in genetic defects or congenital malformations was detected among children conceived to parents who have previously undergone chemotherapy or radiotherapy The use of assisted reproductive technologies and micromanipulation techniques might increase this risk; hence caution should be exercised In female cancer patients, miscarriage and congenital malformations are not increased following chemotherapy However, when IVF and embryo cryopreservation is practised between or shortly after treatment, possible genetic risks to the growing oocytes exist, and hence the babies should be screened During pregnancy, the potential teratogenic effects of chemotherapy influence the choice and timing of therapy Termination is usually recommended in the first trimester Second- and third-trimester exposure does not usually increase the teratogenic risk and cognitive development, but it may increase the risk of poor obstetric outcome and fetal myelosuppression During the first two weeks after fertilization of the embryo, radiation is lethal but not teratogenic High doses of radiation during pregnancy induce anomalies, impaired growth and mental retardation, and there may be an increased risk of childhood leukaemia and other tumours in the offspring

187 citations

Journal ArticleDOI
TL;DR: These data show for the first time that impaired clot formation during thrombocytopenia improves with administration of fibrinogen concentrate, which results in a slowdown of blood loss and prolonged survival.

176 citations

Journal ArticleDOI
TL;DR: As of the end of 2020, the State of Israel, with a population of 9.3 million, had administered more COVID-19 vaccine doses than all countries aside from China, the US, and the UK as mentioned in this paper.
Abstract: As of the end of 2020, the State of Israel, with a population of 9.3 million, had administered more COVID-19 vaccine doses than all countries aside from China, the US, and the UK. Moreover, Israel had administered almost 11.0 doses per 100 population, while the next highest rates were 3.5 (in Bahrain) and 1.4 (in the United Kingdom). All other countries had administered less than 1 dose per 100 population.While Israel's rollout of COVID-19 vaccinations was not problem-free, its initial phase had clearly been rapid and effective. A large number of factors contributed to this early success, and they can be divided into three major groups.The first group of factors consists of long-standing characteristics of Israel which are extrinsic to health care. They include: Israel's small size (in terms of both area and population), a relatively young population, relatively warm weather in December 2020, a centralized national system of government, and well-developed infrastructure for implementing prompt responses to large-scale national emergencies.The second group of factors are also long-standing, but they are health-system specific. They include: the organizational, IT and logistical capacities of Israel's community-based health care providers, the availability of a cadre of well-trained, salaried, community-based nurses who are directly employed by those providers, a tradition of effective cooperation between government, health plans, hospitals, and emergency care providers - particularly during national emergencies; and support tools and decisionmaking frameworks to support vaccination campaigns.The third group consists of factors that are more recent and are specific to the COVID-19 vaccination effort. They include: the mobilization of special government funding for vaccine purchase and distribution, timely contracting for a large amount of vaccines relative to Israel's population, the use of simple, clear and easily implementable criteria for determining who had priority for receiving vaccines in the early phases of the distribution process, a creative technical response that addressed the demanding cold storage requirements of the Pfizer-BioNTech COVID-19 vaccine, and well-tailored outreach efforts to encourage Israelis to sign up for vaccinations and then show up to get vaccinated.While many of these facilitating factors are not unique to Israel, part of what made the Israeli rollout successful was its combination of facilitating factors (as opposed to each factor being unique separately) and the synergies it created among them. Moreover, some high-income countries (including the US, the UK, and Canada) are lacking several of these facilitating factors, apparently contributing to the slower pace of the rollout in those countries.

176 citations


Authors

Showing all 1636 results

NameH-indexPapersCitations
Gideon Koren129199481718
Yuman Fong12586563931
Jeffrey M. Hausdorff10640152287
Yehuda Carmeli8835137154
Aaron Cohen7841266543
Igor M. Sokolov6967320256
Asher Ornoy6736713274
Robert H. Belmaker6543619583
Adam P. Dicker6550216964
Hagit Cohen6421913079
Jose Bras6018720081
Moshe Kotler5925711376
Baruch Modan5920218447
Zvi Laron5851114532
Roz Shafran5724020092
Network Information
Related Institutions (5)
Centers for Disease Control and Prevention
82.5K papers, 4.4M citations

81% related

University Medical Center Groningen
30.3K papers, 967K citations

81% related

VU University Medical Center
22.9K papers, 1.1M citations

80% related

World Health Organization
22.2K papers, 1.3M citations

80% related

University of Maryland, Baltimore
64.7K papers, 2.9M citations

80% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20232
202211
2021171
2020105
2019105
201888